Lexaria Bioscience Corp. (LEXX)
| Market Cap | 33.13M |
| Revenue (ttm) | 825,456 |
| Net Income (ttm) | -3.56M |
| Shares Out | 5.18M |
| EPS (ttm) | -0.97 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $6.83 |
| Previous Close | $6.42 |
| Change ($) | 0.41 |
| Change (%) | 6.39% |
| Day's Open | 6.50 |
| Day's Range | 6.39 - 6.83 |
| Day's Volume | 217,411 |
| 52-Week Range | 3.98 - 12.50 |
Additionally, second patent award received in Japan KELOWNA, BC / ACCESSWIRE / July 27, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in d...
KELOWNA, BC / ACCESSWIRE / July 26, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the rec...
All objectives evaluating DehydraTECH ™ drug delivery platform successfully achieved KELOWNA, BC / ACCESSWIRE / July 22, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Le...
Lexaria Bioscience Corp. (NASDAQ:LEXX) shares are trading higher after the company announced its DehydraTECH significantly enhances delivery of colchicine in study VIRAL-A20-3. This study demonstrated t...
Possible Benefits for Treating SARS-CoV-2/COVID-19 and mRNA Vaccine Side Effects KELOWNA, BC / ACCESSWIRE / July 21, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexari...
Lexaria Bioscience Corp (NASDAQ: LEXX) has announced results from its antiviral drug molecular characterization study VIRAL-MC21-1, completed by Canada's federally funded research organization, the Nati...
VIRAL-MC21-1 Demonstrates Stability of DehydraTECH™-Enabled Antiviral Drugs KELOWNA, BC / ACCESSWIRE / July 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), ...
New patent granted in Japan adds to existing patents in the EU, the U.S., India and Australia KELOWNA, BC / ACCESSWIRE / July 13, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Compan...
KELOWNA, BC / ACCESSWIRE / July 5, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that on Jun...
KELOWNA, BC / ACCESSWIRE / June 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results...
New York, New York--(Newsfile Corp. - June 17, 2021) - PCG Digital -- Lexaria Bioscience Corp. (NASDAQ: LEXX) hit a major milestone this week with their patented DehydraTECHTM technology. An IC50 in vit...
Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs
DehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2 KELOWNA, BC / ACCESSWIRE / June 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NAS...
All studies are using DehydraTECH™ 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine These studies are part of Lexaria's 2021 applied R&D pr...
Dosing Is Complete in First of Three Human Clinical Studies Hoped To Validate Lexaria's Patented Technology for Hypertension Relief Study Tested an Advanced “DehydraTECH™ 2.0” CBD Formulation Second Hum...
Lexaria Bioscience Corp. (NASDAQ: LEXX) C hairman and CEO Chris Bunka began the Benzinga Global Small Cap Business Conference presentation on May 13, 2021, by clarifying a few key details about the comp...
KELOWNA, BC / ACCESSWIRE / June 3, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that remdes...
Developing a safe and effective drug is important, but it's only part of the picture. For the therapeutic effect of a drug to be effective, it largely depends on the delivery system.
New formulation delivers up to 2,708% more CBD into bloodstream* Human clinical hypertension study HYPER-H21-1 also progressing KELOWNA, BC / ACCESSWIRE / May 20, 2021 / Lexaria Bioscience Corp. (NASDAQ...
New patent granted in India bolsters worldwide patent coverage, adding to existing patents in the EU, the U.S., and Australia KELOWNA, BC / ACCESSWIRE / May 12, 2021 / Lexaria Bioscience Corp. (NASDAQ:L...
Phoenix, Arizona--(Newsfile Corp. - May 7, 2021) - The Stock Day Podcast welcomed Lexaria Bioscience Corp. (NASDAQ: LEXX) ("the Company"), a company with a proprietary drug delivery technology, DehydraT...
Up to 2,178% more CBD delivered into bloodstream* Up to 1,737% more CBD delivered into brain tissue* KELOWNA, BC / ACCESSWIRE / May 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:L...
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2021) - Lexaria Bioscience Corp. (CSE: LXX) (NASDAQ: LEXX) - Chris Bunka, CEO and Chairman of Lexaria Bioscience, speaks about the Company's prop...
Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) revealed that its first human clinical trial assessing its DehydraTECH CBD technology to treat high blood pressure - HYPER-H21-1 - is now officially unde...
Study to examine DehydraTECHTM CBD's ability to control blood pressure First of three human clinical studies hoped to validate Lexaria's patented technology for hypertension relief KELOWNA, BC / ACCESSW...
KELOWNA, BC / ACCESSWIRE / April 15, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the appoi...
New York, New York--(Newsfile Corp. - April 15, 2021) - PCG Digital -- Hypertension, or high blood pressure, is known as the "silent killer" because it causes more than 7 million deaths each year-often...
Lexaria Bioscience Corp (NASDAQ:LEXX) (CSE:LXX) announced that its corporate client Amari Corp's "Everyday Calm" CBD product was named a Top CBD Product Pick by New Hope Network, host of the industry-le...
DehydraTECHTM Powers Amari's Award-Winning Products KELOWNA, BC / ACCESSWIRE / April 14, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innov...
New York, New York--(Newsfile Corp. - April 8, 2021) - PCG Digital -- The team at Lexaria Bioscience (NASDAQ: LEXX), a leader in cannabinoid research, has been thinking outside the box. Utilizing Dehyd...
Lexaria Bioscience Corp (NASDAQ:LEXX) (CSE:LXX), a global innovator in drug delivery platforms, said Tuesday it will begin important new applied research and development study programs. In a statement...
Undertaking new 2021 R&D programs in additional drug markets with combined market potential of $87 Billion. KELOWNA, BC / ACCESSWIRE / April 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW...
Lexaria Bioscience Corp (NASDAQ:LEXX) (CSE:LXX) shared Wednesday positive results from its extended stability testing, which showed unparalleled stability for bottled CBD drinks made using its technolog...
Lexaria Technology Generates Positive Stability Testing for World-Class Ready-to-Drink CBD Beverages
DehydraTECHTM CBD-Beverage Demonstrates 93.4% Potency One Year After Production Lexaria's Nanoemulsification Processing Technique Ensures Content Uniformity and Homogeneity of CBD Distribution Without N...
Lexaria Bioscience Corp (NASDAQ:LEXX) (CSE:LXX) (OTCMKTS:LXR) announced Tuesday extensive progress in two of the four planned antiviral drug studies in its 2021 applied research and development (R&D) pr...
10.30am: Proactive North America headlines: Neo Lithium Corp (CVE:NLC) (OTCQX:NTTHF) (FRA:NE2) closes its C$2.6M equity financing with Chinese investor CATL GlobeX Data Ltd (OTCQB:SWISF) (CSE:SWIS) rece...
Two of the four planned studies progressing to examine DehydraTECH™ with antivirals targeting SARS-CoV-2 / COVID-19 . KELOWNA, BC / ACCESSWIRE / March 16, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(N...
Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) has updated investors on the progress of assessing its DehydraTECH CBD technology in treating high blood pressure, noting that all five of its planned st...
Five studies underway to examine DehydraTECHTM CBD for Hypertension. KELOWNA, BC / ACCESSWIRE / March 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"...
Lexaria recently expanded its hypertension R&D program evaluating effectiveness of DehydraTECH-processed CBD to three human clinical studies and two animal studies KELOWNA, BC / ACCESSWIRE / March 11, 2...
Novel drug delivery platform DehydraTECH masks unwanted tastes, improves onset speed, increases bioavailability of active ingredients Cannabis is the current focus, but company eyeing massive markets su...
VANCOUVER, BC, Feb. 16, 2021 /PRNewswire/ - Lexaria Bioscience's (NASDAQ: LEXX) (CSE: LEXX) drug delivery technology, DehydraTECHTM improves the "bioavailability" of pharmaceutical ingredients. "Bioavai...
Lexaria Bioscience Corp (NASDAQ:LEXX) (CSE:LXX) is expanding its applied research and development (R&D) program in 2021 with a particular focus on DehydraTECH-enabled CBD for hypertension, the company a...
New York, New York--(Newsfile Corp. - February 9, 2021) - PCG Digital - Chris Bunka is a happy man. As CEO of Lexaria Bioscience (NASDAQ: LEXX) since 2006, he's battled to legitimize cannabinoids as a m...
Phoenix, Arizona--(Newsfile Corp. - January 28, 2021) - The Stock Day Podcast welcomed Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) ("the Company"), a company with the proprietary drug delivery te...
KELOWNA, BC / ACCESSWIRE / January 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to ann...
KELOWNA, BC / ACCESSWIRE / January 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company") today announced the closing of its previously announced underwritten public of...
KELOWNA, BC / ACCESSWIRE / January 12, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company") today announced that its common stock and warrants will begin trading on the N...
About LEXX
Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.
| Industry Packaged Foods | Founded 2004 |
| Stock Exchange NASDAQ | Ticker Symbol LEXX |
Financial Performance
In 2020, LEXX's revenue was $384,543, an increase of 72.74% compared to the previous year's $222,610. Losses were -$4.08 million, -1.77% less than in 2019.